Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy. 
 

Cardiologist Nathaniel Lebowitz, MD, reviews the latest updates in lipoprotein(a) awareness, testing and drug development.

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.

At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.